Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Going tubeless just got easier for diabetes patients. The FDA has cleared a tubeless cartridge and infusion set for the Tandem Mobi insulin pump, giving users the flexibility to ditch the tubing entirely. The device uses smart technology to predict glucose levels and auto-adjust insulin delivery — and it's expected to hit pharmacies in early 2027.
Going tubeless just got easier for diabetes patients. The FDA has cleared a tubeless cartridge and infusion set for the Tandem Mobi insulin pump, giving people living with diabetes more flexibility in how they manage their condition. Users can now convert the existing tubed Tandem Mobi pump into a fully tubeless device — a meaningful quality-of-life upgrade for many.
The Tandem Mobi system runs on Control-IQ+ technology, which predicts glucose levels up to 30 minutes ahead and automatically adjusts insulin delivery using continuous glucose monitoring (CGM) data. It also syncs with a smartphone app, making it one of the more tech-forward options on the market. Tandem bills Mobi as the smallest insulin pump currently available.
By the Numbers:
Why it matters: More wear options mean more people can find a setup that fits their lifestyle, potentially improving adherence and outcomes for the millions managing diabetes with insulin pump therapy.
